HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia

Atherosclerosis

Volumn 150, Issue 1, 2000, Pages 113-120

  Winkler, K ^a   Schaefer, J R ^b   Klima, B ^a   Nuber, C ^a   Friedrich, I ^a   Koster W ^a   Gierens, H ^a   Scharnagl, H ^a   Soufi, M ^b   Wieland, H ^a   Marz W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Apolipoprotein A I; Cholesterol lowering drugs; In vivo kinetics; Stable isotopes

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; BUTANOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYBENZOIC ACID DERIVATIVE; LIFIBROL;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; HYPERLIPOPROTEINEMIA TYPE 5; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; BUTANOLS; CHOLESTEROL, HDL; HUMANS; HYDROXYBENZOIC ACIDS; HYPERLIPOPROTEINEMIA TYPE II; HYPERLIPOPROTEINEMIA TYPE V; MALE; MIDDLE AGED;

EID: 0034185611     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00351-2     Document Type: Article

References (45)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 1994;344:1383-1389.
2. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. New Engl J Med 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. New Engl J Med 1996;335:1001-9.
4. Miller GJ, Miller NE. Plasma-high density-lipoprotein concentration and development of ischemic heart-disease. Lancet 1975;1:16-9.
5. Gordon DJ, Rifkind BM. High-density lipoprotein -the clinical implications of recent studies. New Engl J Med 1989;321:1311-6.
6. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. New Engl J Med 1991;325:373-81.
7. Coleman MP, Key TJA, Wang DY. A prospective study of obesity, lipids, apolipoproteins and ischemic heart disease in women. Atherosclerosis 1992;92:177-85.
8. Sigurdsson GA, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992;69:1251-4.
9. Schliack M, Löser R, Seibel K, Blay KH. Hypolipidemic activity of K12.148 in rats, marmosets and pigs. Artery 1989;16:90-104.
10. Locker PK, Jungbluth GL, Francom SF, Hughes GS, for the Lifibrol study group. Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolaemia, Clin. Pharmacol. Ther. 1995;57:73-88.
11. Scharnagl H, März W, Wieland H. Lifibrol: first member of a new class of lipid-lowering drugs? Exp Opin Invest Drugs 1997;6:583-91.
12. Winkler K, Schaefer JR, Klima B, Nuber C, Sattler A, Friedrich I, Köster W, Steinmetz A, Wieland H, März W. Lifibrol enhances the LDL apoB-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis 1999;144:167-75.
13. Schaefer JR, Rader DJ, Ikewaki K, Fairwell T, Zech LA, Kindt MR, Davignon J, Gregg RE, Brewer Jr. HB In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. Arterioscler Thromb 1992;12:843-8.
14. Schaefer JR, Scharnagl H, Baumstark MW, Schweer H, Zech LA, Seyberth H, Winkler K, Steinmetz A, März W. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vase Biol 1997;17:348-53.
15. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest 1955;34:1345-53.
16. Laemmli UK Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1979;227:680-5.
17. Cobelli CC, Toffolo G, Foster DM. Tracer to tracee ratio for analysis of stable isotope tracer data: link with radiotracer formalism. Am J Physiol 1992;262:E968-75.
18. Schaefer JR, Rader DJ, Brewer Jr HB. Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. Curr Opin Lipidol 1993;3:227-32.
19. Cobelli C, Toffolo G, Bier DM, Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am J Physiol 1987;253:E551-64.
20. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer Jr. HB Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 1993;34:2207-15.
21. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apoA-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 1990;85:804-11.
22. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 1994;35:2083-93.
23. Tilly-Kiesi M, Lichtenstein AH, Ordovas JM, Dolnikowski G, Malmström R, Taskinen M-R, Schaefer EJ. Subjects with apoA-I(Lys107→0) exhibit enhanced fractional catabolic rate of apoA-I in Lp(AI) and apoA-II in Lp(AI with AI). Arterioscler Thromb Vase Biol 1997;17:873-80.
24. Hasibeder H, Staab HJ, Seibel K, Schmidle G, März W. Clinical pharmacology of the hypocholesterolemic agent K12.148 (Lifibrol) in healthy volunteers. Eur J Clin Pharmacol 1991;40(Suppl.1):S91-4.
25. Ginsberg HN, Ngai C, Ramakrishnan R. Lovastatin increases apolipoprotein A-I levels in subjects with isolated reductions in high density lipoproteins. Circulation: II 1991;84:140.
26. Schaefer JR, Schweer H, Ikewaki K, Stracke H, Seyberth HJ, Kaffarnik H, Maisch B, Steinmetz A. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999;144:177-84.
27. Schaefer EJ, Zech LA, Jenkins LL, Bronzert TJ, Rubalcaba EA, Lindgren FT, Aamodt RL, Brewer Jr HB. Human apolipoprotein A-I and A-II metabolism. J Lipid Res 1982;23:850-62.
28. Brinton EA, Eisenberg S, Breslow JL. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest 1989;84:262-9.
29. Gylling H, Vega GL, Grundy SM. Physicologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res 1992;33:1527-39.
30. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of Gemfibrozil on lipoprotein metabolism. J Clin Invest 1985;75:1702-12.
31. Jin F-Y, Kamanna VS, Mei-Yu C, Kengathevy M, Kashyap ML. Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (HepG2). Arterioscler Thromb Vase Biol 1996;16:1052-62.
32. Kashyap ML, Saku K. HDL metabolism in HDL deficiency associated with familial hypertriglyceridemia: effect of treatment with Gemfibrozil. Adv Exp Med Biol 1991;285:233-6.
33. Malmendier CL, Delcroix C. Effects of Fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985;5:161-9.
34. Glomset JA. The plasma lecithin: cholesterol acyltransferase reaction. J Lipid Res 1968;9:155-67.
35. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
36. Johnson WJ, Mahlberg FH, Rothblat GH, Phillips MC. Cholesterol transport between cells and high density lipoproteins. Biochim Biophys Acta 1991;1085:273-98.
37. Pieters MN, Scheuten D, VanBerkel TJC. In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta 1994;1225:125-34.
38. Rader DJ, Ikewaki K. Unraveling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol 1996;7:117-23.
39. Franceschini G. Apolipoprotein function in health and disease. Insights from natural mutations. Eur J Clin Invest 1996;26:733-46.
40. Holvoet P, Zhao Z, Deridder E, Dhoest A, Collen D. Effects of deletion of the carboxy-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association. J Biol Chem 1996;271:19395-401.
41. Calabresi C, Franceschini G. High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Curr Opin Lipidol 1997;8:219-24.
42. Frederickson DS, Altrocchi PH, Avidi LV, Goodman DS, Goodman HC. Tangier disease-combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1961;55:1016-31.
43. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith Jr MP, Pritchard PH, Frohlich J, Lees RS, Barnard GF, Ordovas JM, Schaefer EJ. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994;107:85-98.
44. Schaefer JR, Rader DJ, Gregg RE. In vitro apo B-100 and apo A-I kinetics in Tangier disease utilizing a stable isotope technique. Circulation 1990;82(III):447.
45. Zech LA, Schaefer EJ, Bronzert TJ, Aamodt RL, Brewer Jr HB. Metabolism of human apolipoproteins A-I and A-II. Compartmental models. J Lipid Res 1983;24:60-71.